Abstract Number: 881 • 2015 ACR/ARHP Annual Meeting
ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis
Background/Purpose: ANCA associated vasculitis (AAV) is known as a systemic vasculitis with unknown etiology. Recently, relationship between AAV and complement have been shown and complement…Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting
Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…Abstract Number: 887 • 2015 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients
Background/Purpose: Despite recent therapeutic advances in treating ANCA-associated vasculitides (AAVs), some patients relapse or require long-term immunosuppression, leading to significant morbidity and mortality. IVIg represents…Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5+ b-Cells in ANCA-Associated Vasculitis
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…Abstract Number: 1764 • 2014 ACR/ARHP Annual Meeting
Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis
Background/Purpose Objective: To compare various factors including clinical manifestations, laboratory data and mortality in between two groups of patients with anti-neutrophil cytoplasmic antibody (ANCA) positive…Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Background/Purpose: Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…Abstract Number: 85 • 2014 ACR/ARHP Annual Meeting
Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population
Background/Purpose Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority…Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting
Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- Next Page »